Stock listing
NASDAQ:SCLX Scilex Holding Company Stock
Home listing (NASDAQ) of Scilex Holding Company
Follow Scilex Holding Company into a list and get an email when it puts out news.
Share price · NASDAQ:SCLX
$0.566 USD -0.062 (-9.8%)
Close on Nov 20, 2026
- Day range
- $0.500 – $0.631 USDNov 20, 2026
- Volume
- 198,279 sharesNov 20, 2026
- Market cap
- $3.98M USDAt the close on Nov 20, 2026 · price × 7.03M shares outstanding
- 52-week range
- $0.500 – $16.812 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $148,441 USDMedian day 35,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SCLX · Home | $0.566 USD | -0.062 (-9.8%) | 198,279 | $0.613 | $0.631 | $0.500 | $0.627 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SCLX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.566 | -0.062 | -9.8% | $0.613 | $0.631 | $0.500 | 198,279 | |
| $0.627 | -0.015 | -2.3% | $0.642 | $0.685 | $0.580 | 188,813 | |
| $0.642 | -0.608 | -48.6% | $1.230 | $1.230 | $0.543 | 639,624 | |
| $1.250 | -0.180 | -12.6% | $1.390 | $1.390 | $1.240 | 90,573 | |
| $1.430 | -0.130 | -8.3% | $1.550 | $1.570 | $1.402 | 58,943 | |
| $1.560 | -0.060 | -3.7% | $1.610 | $1.658 | $1.540 | 48,228 | |
| $1.620 | +0.010 | +0.6% | $1.620 | $1.652 | $1.610 | 11,800 | |
| $1.610 | -0.130 | -7.5% | $1.740 | $1.775 | $1.610 | 30,900 | |
| $1.740 | +0.040 | +2.4% | $1.690 | $1.770 | $1.640 | 23,300 | |
| $1.700 | 0.000 | 0.0% | $1.700 | $1.780 | $1.665 | 20,800 | |
| $1.700 | -0.130 | -7.1% | $1.830 | $1.830 | $1.610 | 79,900 | |
| $1.830 | -0.020 | -1.1% | $1.950 | $1.990 | $1.810 | 32,900 | |
| $1.850 | -0.020 | -1.1% | $1.850 | $2.000 | $1.850 | 46,200 | |
| $1.870 | +0.020 | +1.1% | $1.880 | $2.090 | $1.850 | 54,900 | |
| $1.850 | -0.210 | -10.2% | $2.050 | $2.064 | $1.830 | 49,600 | |
| $2.060 | -0.030 | -1.4% | $2.090 | $2.170 | $2.050 | 7,400 | |
| $2.090 | +0.040 | +2.0% | $2.010 | $2.100 | $2.010 | 17,000 | |
| $2.050 | -0.280 | -12.0% | $2.320 | $2.340 | $2.010 | 99,300 | |
| $2.330 | -0.020 | -0.9% | $2.350 | $2.400 | $2.280 | 37,900 | |
| $2.350 | -0.120 | -4.9% | $2.440 | $2.480 | $2.270 | 35,200 | |
| $2.470 | -0.090 | -3.5% | $2.560 | $2.600 | $2.449 | 33,300 | |
| $2.560 | +0.030 | +1.2% | $2.510 | $2.620 | $2.510 | 25,900 | |
| $2.530 | -0.040 | -1.6% | $2.550 | $2.680 | $2.520 | 35,700 | |
| $2.570 | -0.260 | -9.2% | $2.810 | $2.810 | $2.518 | 52,100 | |
| $2.830 | +0.010 | +0.4% | $2.820 | $2.890 | $2.770 | 29,500 | |
| $2.820 | -0.030 | -1.1% | $2.830 | $2.850 | $2.770 | 12,500 | |
| $2.850 | -0.030 | -1.0% | $2.880 | $2.950 | $2.810 | 26,700 | |
| $2.880 | +0.080 | +2.9% | $2.810 | $3.225 | $2.790 | 33,900 | |
| $2.800 | -0.120 | -4.1% | $2.920 | $2.950 | $2.800 | 33,800 | |
| $2.920 | -0.040 | -1.4% | $2.960 | $3.110 | $2.860 | 49,700 | |
| $2.960 | -0.530 | -15.2% | $3.490 | $3.592 | $2.900 | 140,800 | |
| $3.490 | -0.470 | -11.9% | $3.900 | $3.900 | $3.445 | 82,100 | |
| $3.960 | +0.140 | +3.7% | $3.870 | $4.050 | $3.790 | 57,900 | |
| $3.820 | -0.240 | -5.9% | $4.130 | $4.490 | $3.810 | 59,600 | |
| $4.060 | -0.350 | -7.9% | $4.400 | $4.589 | $4.000 | 107,800 | |
| $4.410 | -0.040 | -0.9% | $4.490 | $4.879 | $4.400 | 16,100 | |
| $4.450 | +0.040 | +0.9% | $4.420 | $4.690 | $4.400 | 17,500 | |
| $4.410 | -0.080 | -1.8% | $4.480 | $4.535 | $4.358 | 12,000 | |
| $4.490 | -0.400 | -8.2% | $4.890 | $4.900 | $4.450 | 73,200 | |
| $4.890 | -0.050 | -1.0% | $5.366 | $5.366 | $4.830 | 42,800 | |
| $4.940 | -0.160 | -3.1% | $5.060 | $5.151 | $4.920 | 27,300 | |
| $5.100 | -0.250 | -4.7% | $5.350 | $5.350 | $5.100 | 8,700 | |
| $5.350 | +0.190 | +3.7% | $5.120 | $5.420 | $5.120 | 17,900 | |
| $5.160 | +0.120 | +2.4% | $5.020 | $5.306 | $5.000 | 21,500 | |
| $5.040 | -0.330 | -6.1% | $5.360 | $5.460 | $5.020 | 27,000 | |
| $5.370 | +0.200 | +3.9% | $5.220 | $5.600 | $5.220 | 40,000 | |
| $5.170 | +0.240 | +4.9% | $4.970 | $5.350 | $4.970 | 41,200 | |
| $4.930 | -0.170 | -3.3% | $5.100 | $5.220 | $4.850 | 42,900 | |
| $5.100 | +0.090 | +1.8% | $4.990 | $5.200 | $4.899 | 24,900 | |
| $5.010 | -0.040 | -0.8% | $5.115 | $5.190 | $5.000 | 21,600 | |
| $5.050 | -0.150 | -2.9% | $5.190 | $5.220 | $5.050 | 20,600 | |
| $5.200 | -0.170 | -3.2% | $5.370 | $5.425 | $5.190 | 25,200 | |
| $5.370 | -0.045 | -0.8% | $5.410 | $5.500 | $5.300 | 39,000 | |
| $5.415 | +0.135 | +2.6% | $5.410 | $5.720 | $5.290 | 40,400 | |
| $5.280 | -0.070 | -1.3% | $5.370 | $5.450 | $5.280 | 15,000 | |
| $5.350 | -0.050 | -0.9% | $5.420 | $5.645 | $5.270 | 30,500 | |
| $5.400 | -0.095 | -1.7% | $5.510 | $5.510 | $5.330 | 41,900 | |
| $5.495 | +0.065 | +1.2% | $5.410 | $5.530 | $5.290 | 32,700 | |
| $5.430 | -0.140 | -2.5% | $5.570 | $5.850 | $5.400 | 46,700 | |
| $5.570 | -0.040 | -0.7% | $5.650 | $5.850 | $5.557 | 62,800 | |
| $5.610 | -0.040 | -0.7% | $5.640 | $6.200 | $5.590 | 65,000 | |
| $5.650 | -0.010 | -0.2% | $5.680 | $5.882 | $5.560 | 20,939 | |
| $5.660 | -0.070 | -1.2% | $5.790 | $5.800 | $5.500 | 58,341 | |
| $5.730 | -0.070 | -1.2% | $5.800 | $5.910 | $5.640 | 26,000 | |
| $5.800 | +0.150 | +2.7% | $5.650 | $5.800 | $5.465 | 29,700 |
Splits
2 splits since 2025 · NASDAQ:SCLX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 53-for-33 | Split | |
| 1-for-35 | Consolidation |
- Ticker
- NASDAQ:SCLX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jun 16, 2026
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Latest news
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Jul 7, 2026
Closed $9.93 (+23.0%) on Jul 7, 2026
Issued by another party
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Jun 16, 2026
Closed $5.88 (+18.8%) on Jun 16, 2026
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Jun 12, 2026
Closed $5.29 (-2.3%) on Jun 12, 2026
Scilex Holding Company Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock
Jun 5, 2026
Closed $4.36 (-7.7%) on Jun 5, 2026
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
May 22, 2026
Closed $3.80 (+3.2%) on May 22, 2026
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
May 5, 2026
Closed $6.68 (-3.8%) on May 5, 2026
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Re...
May 4, 2026
Closed $6.94 (+5.4%) on May 4, 2026
Scilex Holding Company on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 17 in the last 12 months · 153 in all · newest Jul 7, 2026 · oldest 2021
- Decks
- 21 decks · latest January 2025
Where Scilex Holding Company is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SCLX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SCLX | BOATS | United States | USD |
| Tradegate:D8B0 | Tradegate | Germany | EUR |
| Frankfurt:D8B0 | Frankfurt | Germany | EUR |
| Dusseldorf:D8B0 | Dusseldorf | Germany | EUR |
Valuation
EV/sales 3.1× against a median of 1.3×: 7th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $98.96M USD
- P/E
- Loss
- EV/sales
- 3.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 161.1%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.46
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Scilex Holding Company · NASDAQ:SCLX | US$3.98M | US$98.96M | n/a | 3.1× | n/a | n/a | n/a | n/a | 1.46 |
| ChoA Pharmaceutical Co., Ltd. · KRX:034940 | US$6.55M | US$6.85M | n/a | 0.1× | n/a | 0.3× | −4.6% | 0.1× | n/a |
| Newbury Pharmaceuticals AB · OMXSTO:NEWBRY | US$5.78M | US$4.87M | n/a | 1.2× | n/a | 3.0× | −53.7% | 0.0× | n/a |
| Firebrick Pharma Limited · ASX:FRE | US$5.52M | US$4.64M | n/a | 66.0× | n/a | 5.0× | n/a | 0.0× | n/a |
| Universe Pharmaceuticals INC · NASDAQ:UPC | US$5.41M | −US$14.09M | n/a | 0.0× | n/a | 0.1× | −20.6% | 0.2× | 0.91 |
| Mangalam Drugs & Organics Ltd. · NSE:MANGALAM | US$4.71M | US$4.71M | n/a | 0.2× | n/a | 0.4× | −16.5% | 0.0× | n/a |
| Vivimed Labs Limited · NSE:VIVIMEDLAB | US$4.49M | US$46.54M | n/a | 6.2× | n/a | n/a | −252.1% | n/a | n/a |
| Acrux Limited · ASX:ACR | US$4.06M | US$4.60M | n/a | 1.5× | n/a | 4.2× | −13.0% | 1.7× | n/a |
| Scienture Holdings, Inc. · NASDAQ:SCNX | US$3.74M | US$8.36M | n/a | 5.6× | n/a | 0.1× | n/a | 0.2× | 1.74 |
| Sanai Health Industry Group Company Limited · HKEX:1889 | US$2.42M | −US$44.72M | n/a | −3.5× | n/a | 0.1× | −25.7% | 0.0× | n/a |
| Lasa Supergenerics Ltd. · NSE:LASA | US$2.17M | US$2.17M | n/a | 3.2× | n/a | 0.4× | −260.4% | 0.0× | n/a |
| Median of the others | US$4.60M | US$4.67M | 1.3× | 0.4× | −23.1% | 0.0× | 1.33 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 490.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.89 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Henry Ji | Executive Chairman, Chief Executive Officer and President |
Board
| Director | Role |
|---|---|
| Henry Ji | Executive Chairman, Chief Executive Officer and President |
| Alexander Wu | Director |
| Dorman Followwill+ | Director |
| Jay Chun | Director |
| Yue Alexander Wu | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 20, 2026 | |
| Q2 2026 | Aug 14, 2026 | −5.0% |
| Q1 2026 | Apr 10, 2026 · After close | −12.3% |
| Q4 2025 | Feb 25, 2026 | −0.5% |
| Q3 2025 | Nov 14, 2025 · After close | −12.3% |
| Q2 2025 | Aug 13, 2025 · After close | −17.3% |
| Q1 2025 | May 14, 2025 · After close | −7.8% |
| Q4 2024 | Mar 31, 2025 · After close | −4.4% |
| Q3 2024 | Nov 27, 2024 | +0.6% |
| Q2 2024 | Aug 13, 2024 · After close | −4.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | −0.6% |
| Q4 2023 | Mar 12, 2024 · Before open | −5.7% |
| Q3 2023 | Nov 14, 2023 · After close | +2.5% |
| Q2 2023 | Aug 30, 2023 | −4.8% |
| Q1 2023 | May 12, 2023 | +24.5% |
| Q4 2022 | Mar 7, 2023 | −12.3% |
| Q3 2022 | Nov 4, 2022 | −12.1% |
| Q2 2022 | Aug 12, 2022 | 0.0% |
| Q1 2022 | May 16, 2022 | 0.0% |
| Q4 2021 | Feb 24, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2025) | Investor deck | 57 slides | January 2025 |
| Merger or Acquisition (September 2024) | Merger or acquisition | 22 slides | Sep 3, 2024 |
| Investor Presentation (September 2024) | Investor deck | 29 slides | September 2024 |
| Investor Presentation (April 2024) | Investor deck | 33 slides | April 2024 |
| Investor Presentation (January 2024) | Investor deck | 41 slides | January 2024 |
| Investor Presentation (November 2023) | Investor deck | 43 slides | Nov 1, 2023 |
| Investor Presentation (October 2023) | Investor deck | 42 slides | October 2023 |
| Investor Presentation (October 2023) | Investor deck | 42 slides | October 2023 |
| Investor Presentation (October 2023) | Investor deck | 41 slides | October 2023 |
| Investor Presentation (July 2023) | Investor deck | 42 slides | July 2023 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2023) | Investor deck | 42 slides | Jun 22, 2023 |
| Investor Presentation (May 2023) | Investor deck | 35 slides | May 2023 |
| Investor Presentation (May 2023) | Investor deck | 39 slides | May 2023 |
| Investor Presentation (March 2023) | Investor deck | 31 slides | March 2023 |
| Investor Presentation (March 2023) | Investor deck | 26 slides | March 2023 |
| Investor Presentation (2023) | Investor deck | 56 slides | 2023 |
| Investor Presentation (December 2022) | Investor deck | 25 slides | December 2022 |
| SPAC Merger (March 2022) | SPAC merger | 21 slides | Mar 18, 2022 |
| SPAC Merger (February 2022) | SPAC merger | 57 slides | Feb 18, 2022 |
| SPAC Merger (December 2021) | SPAC merger | 57 slides | December 2021 |
| Investor Presentation (April 2019) | Investor deck | 27 slides | April 2019 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of newly issued shares of common stock Announced: US$100M · US$10 a share Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of Semnur common stock) Use of proceeds: Pipeline advancement incl. Phase 3 SEMDEXA (SP-102), commercialization, acquisitions and partnerships, working capital, IP, general corporate purposes | Jul 7, 2026 |
| Strategic investment of common stock Announced: US$100M · US$15 a share Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of common stock at $15.00 per share, approximately 6,666,667 shares) Use of proceeds: Strategic growth, healthcare and medtech initiatives, product development, acquisitions and partnerships, working capital, IP and general corporate purposes | Jul 6, 2026 |
| Warrant exercise of shares of common stock on exercise of existing warrants Closed: US$20.3M raised · US$22.51 a share · Warrants at US$29 for 60 months · Rodman & Renshaw LLC +1 Dealers: Rodman & Renshaw LLC (co-lead), StockBlock Securities LLC (co-lead) Use of proceeds: Working capital and general corporate purposes | Nov 25, 2025 |
| Registered direct offering of common stock, pre-funded warrants and accompanying common warrants Announced: about US$17M · US$0.59 a share · ½ warrant at US$0.649 Use of proceeds: Working capital and general corporate purposes, including commercialization, R&D, clinical trials, acquisitions and debt repayment | Dec 12, 2024 |
| Warrant exercise of outstanding warrants issued in March 2024 Announced: about US$1M · US$0.59 a share | Dec 12, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Vickers Vantage Corp. I, a blank check company (SPAC). Priced at US$10.00 a unit on Jan 6, 2021.
- Price
- US$10.00 a unit
- Units offered
- 12,000,000 units
- Offering size
- US$120 million
- Underwriters' option
- Up to 1,800,000 more units
- Listing
- VCKAU on the Nasdaq Capital Market
- Underwriter
- Maxim Group LLC
- Units delivered
- On or about Jan 11, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 19, 2020 |
| Filed publicly | Dec 15, 2020 |
| Amended once | Dec 28, 2020 |
| Shares registered with an exchange | Jan 6, 2021 |
| Declared effective by the SEC | Jan 6, 2021 |
| Final prospectus, with the price | Jan 8, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 8, 2021 |
| EFFECT · Notice that a registration is effective | Jan 6, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jan 6, 2021 |
| CERT · Exchange's certificate of listing | Jan 6, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 6, 2021 |
| CORRESP · Letter to the SEC | Jan 5, 2021 |
| CORRESP · Letter to the SEC | Jan 5, 2021 |
| CORRESP · Letter to the SEC | Dec 28, 2020 |
| S-1/A · Registration statement, amended | Dec 28, 2020 |
| UPLOAD · Letter from the SEC | Dec 17, 2020 |
All 12 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Dec 15, 2020 |
| DRS · Draft registration statement | Aug 19, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 8, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 30.3M | 56.6M | 46.7M | 38.0M | 31.3M | 23.6M | 21.0M |
| Cost of revenue | 10.6M | 16.7M | 15.7M | 10.8M | 3.63M | 2.15M | 5.80M |
| Gross profit | 125.8M | 167.4M | 31.1M | 27.2M | 27.7M | 21.4M | 15.2M |
| Research and development | 20.7M | 9.64M | 12.7M | 9.05M | 9.20M | 9.96M | 85.5M |
| Selling, general and administrative | 266.9M | 119.0M | 119.6M | 64.9M | 50.6M | 43.0M | 64.7M |
| Operating income | -346.0M | -83.4M | -105.4M | -50.6M | -35.8M | -35.3M | -138.7M |
| Depreciation and amortization | 4.62M | 4.05M | 4.15M | 3.96M | 3.78M | 3.78M | 3.75M |
| EBITDA | -341.4M | -79.3M | -101.3M | -46.7M | -32.1M | -31.5M | -134.9M |
| Interest expense | 11.5M | 1.96M | 1.07M | 9.60M | 11.8M | 13.1M | 16.9M |
| Income before tax | -374.0M | -72.8M | -114.3M | -23.4M | -88.4M | -47.6M | -178.6M |
| Income tax | 26.0K | -1.00K | 13.0K | 4.00K | 5.00K | -53.0K | 2.00K |
| Net income | -374.1M | -72.8M | -114.3M | -23.4M | -88.4M | -47.5M | -178.6M |
| Earnings per share, basic | -36.48 | -7.24 | -1.28 | -0.17 | -0.67 | -0.36 | -44.30 |
| Earnings per share, diluted | -36.48 | -8.05 | -1.28 | -0.17 | -0.67 | -0.36 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.96M | 3.27M | 3.92M | 2.18M | 4.34M | 30.5K | |
| Short-term investments | 6.03M | 303.8K | |||||
| Receivables | 15.2M | 26.4M | 34.6M | 21.2M | 14.3M | 13.1M | |
| Inventory | 4.79M | 2.44M | 4.21M | 1.38M | 2.56M | 1.15M | |
| Current assets | 38.4M | 41.5M | 46.8M | 29.6M | 23.0M | 30.5K | |
| Property, plant and equipment | 13.6M | 708.0K | 722.0K | 772.0K | 805.0K | 2.52M | |
| Goodwill | 13.5M | 13.5M | 13.5M | 13.5M | 13.5M | 13.5M | |
| Total assets | 365.0M | 93.0M | 101.3M | 86.5M | 77.9M | 199.5K | |
| Accounts payable | 86.3M | 52.6M | 41.0M | 8.45M | 4.28M | 8.12M | |
| Current liabilities | 483.7M | 259.6M | 250.4M | 44.8M | 169.4M | 180.8K | |
| Long-term debt | 22.5M | 845.0K | 17.0M | 3.83M | 107.7M | ||
| Total debt | 132.5M | 38.0M | 128.5M | 0 | 110.0M | 138.6M | |
| Total liabilities | 576.7M | 285.6M | 274.2M | 50.3M | 301.8M | 180.8K | |
| Shareholders' equity | -207.8M | -192.6M | -172.9M | 36.2M | -223.9M | 18.7K | |
| Shares outstanding | 7.03M | 5.24M | 100.0M | 141.3M | 132.9M | 3.45M | 4.03M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 3.82M | 19.3M | -20.7M | -21.3M | -28.7M | -31.5M | -60.4M |
| Capital spending | -133.0K | 0 | -30.0K | -7.00K | 0 | -25.0K | -584.0K |
| Free cash flow | 3.68M | 19.3M | -20.7M | -21.3M | -28.7M | -31.5M | -61.0M |
| Cash from investing | 4.08M | -2.67M | -330.0K | -2.07M | 0 | -25.0K | -17.6M |
| Cash from financing | -5.46M | -18.1M | 23.6M | 21.2M | 28.2M | -19.2M | 15.8M |
| Dividends paid | -8.65M | -8.65M | |||||
| Share buybacks | 0 | -10.0M | 96.0K | 140.3M | |||
| Change in cash | 1.68M | -1.46M | 2.54M | -2.15M | -501.0K | -50.7M | -62.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 17, 2026 | Explanation request | SEC |
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| 8-K · Current report | Sep 29, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 22, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 7, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 29, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 12, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 9, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 9, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 26, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 20, 2026 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | May 20, 2026 | Other filings | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | May 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 5, 2026 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 28, 2026 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Apr 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Apr 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Apr 10, 2026 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2026 | Explanation request | SEC |
| 8-K · Current report | Mar 13, 2026 | Current report | SEC |
| 8-K · Current report | Mar 13, 2026 | Current report | SEC |
| 424B3 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 20, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 20, 2026 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Feb 20, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Feb 13, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 8-K · Current report | Feb 2, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| RW · Request to withdraw a registration | Jan 6, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 31, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 29, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 22, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 17, 2025 | Material contract | SEC |
| S-1 · Registration statement | Dec 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 12, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 11, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 5, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Dec 4, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Dec 1, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 1, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Nov 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 28, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 24, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 24, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 24, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 24, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Nov 7, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Nov 4, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 4, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 4, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Oct 31, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 31, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 31, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 31, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 28, 2025 | Meeting notice | SEC |
| D | Oct 14, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2025 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 2, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 1, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 1, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Sep 26, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 26, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 26, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2025 | Acquisition or disposal | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 26, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 26, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 26, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 23, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Aug 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| S-1 · Registration statement | Aug 4, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 23, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 23, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 23, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | May 16, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 16, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 14, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2025 | Other filings | SEC |
| 8-K · Current report | May 12, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| POS AM · Amendment to an effective registration | May 7, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | May 7, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | May 7, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| 8-K · Current report | Apr 21, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 424B3 · Prospectus | Mar 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 3, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 3, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| 8-K · Current report | Mar 3, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Feb 27, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 27, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Feb 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 27, 2025 | Material contract | SEC |
| PRER14A | Feb 26, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Feb 14, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Jan 22, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 22, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2025 | Material contract | SEC |
This page holds 200 of 745 filings. Open Filings
Cap table
Built by 6ix from Scilex Holding Company’s releases · as of Jul 7, 2026
- Common shares
- 7,034,737
- Fully diluted
- 7,034,737
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 7,034,737 |
Warrants and options
| Lot |
|---|
| Warrants · US$29.00 · expire about Nov 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 7,034,737 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Laura J. Hamill Other companies: Fate Therapeutics, Inc. (Board Member · Since at least Jun 12, 2026); Jazz Pharmaceuticals plc (Director, BB Biotech, Fate Therapeutics Inc., and Unchained Labs · Since at least Jul 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 11, 2020); Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past); Acceleron Pharma Inc (Director · Sep 15, 2020 – Nov 19, 2021 · Past); AnaptysBio, Inc. (Director · Sep 24, 2019 – Jan 6, 2023 · Past); Gilead Sciences, Inc. (EVP, Worldwide Commercial Ops · Sep 10, 2018 – May 8, 2019 · Past) | Director · Nov 10, 2022 – Jan 17, 2023 · Past |
| Tommy G Thompson Other companies: Healthpeak Properties, Inc. (Director · Since at least Mar 1, 2024); TherapeuticsMD, Inc. (Director · Since at least Aug 20, 2015); United Therapeutics Corporation (Director · Since at least Jun 26, 2015); Tyme Technologies Inc (Director · Feb 6, 2018 – Aug 22, 2019 · Past); Physicians Realty Trust (Director · Aug 31, 2015 – Mar 1, 2024 · Past); Centene Corporation (Director · Jun 30, 2015 – Dec 31, 2021 · Past) | Director · Nov 10, 2022 – Jan 17, 2023 · Past |
| Elizabeth Czerepak Other companies: TransCode Therapeutics, Inc. (CFO, Director · Since at least Oct 6, 2025); Delcath Systems, Inc. (DIRECTOR · Since at least Feb 14, 2020); Sorrento Therapeutics, Inc. (EVP & Chief Financial Officer · Nov 15, 2021 – May 18, 2022 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 19, 2019 – Jun 18, 2020 · Past) | See Remarks · Nov 10, 2022 – Jan 17, 2023 · Past |
| Jaisim Shah Other companies: Semnur Pharmaceuticals, Inc. (See Remarks, Director · Since at least Sep 22, 2025); Sorrento Therapeutics, Inc. (Director · Sep 9, 2013 – Aug 30, 2021 · Past); Facet Biotech Corp (SVP, Chief Business Officer · Dec 9, 2008 – Dec 9, 2008 · Past); PDL BioPharma Inc (SVP, Mktg & Bus. Affairs · Jan 9, 2006 – Apr 28, 2008 · Past) | See Remarks, Director · Nov 10, 2022 – Dec 18, 2024 · Past |
| Henry Ji Other companies: Semnur Pharmaceuticals, Inc. (Executive Chairman, Chief Executive Officer and President · Since at least Sep 22, 2025); Sorrento Therapeutics, Inc. (Chairman, President and CEO · Since at least Feb 16, 2010); ImmunityBio, Inc. (Director · Jul 27, 2015 – Jul 27, 2015 · Past) | Executive Chairman, Chief Executive Officer and President · Since at least Nov 10, 2022 |
| David Lemus Other companies: Silence Therapeutics PLC (Director · Since at least Jan 2, 2025); Sorrento Therapeutics, Inc. (Director · Sep 26, 2017 – Aug 30, 2021 · Past) | Director · Nov 10, 2022 – Oct 17, 2024 · Past |
| Dorman Followwill Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025); Sorrento Therapeutics, Inc. (Director · Sep 26, 2017 – Aug 30, 2021 · Past) | Director · Since at least Nov 10, 2022 |
| Yue Alexander Wu Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025); Sorrento Therapeutics, Inc. (Director · Aug 1, 2016 – Aug 30, 2021 · Past) | Director · Since at least Sep 22, 2023 |
| Alexander Wu Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Annu Navani Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025) | Director · Jul 21, 2024 – Aug 16, 2024 · Past |
All 18 people
| Person | Seat |
|---|---|
| Jay Chun Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025) | Director · Since at least Sep 22, 2023 |
| Jeffrey Chi Other companies: Aardvark Therapeutics, Inc. (Vice Chairman · Since at least Feb 12, 2025) | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
| Stephen Hoi Other companies: Semnur Pharmaceuticals, Inc. (See Remarks · Since at least Sep 22, 2025) | CFO, COO and Secretary, Director · Since at least Sep 22, 2023 |
| Tien Lee Other companies: Aardvark Therapeutics, Inc. (Chief Executive Officer · Since at least Feb 12, 2025) | Director · Nov 10, 2022 – Jan 17, 2023 · Past |
| Chris Ho | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
| Pei Wei Woo | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
| Steve Myint | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
| Suneel G Kaji | Director · Jan 6, 2021 – Jan 6, 2021 · Past |
Log in to ask 6ix AI your own questions about Scilex Holding Company.